The US House of Representatives passed HR 7608, a four-bill appropriations minibus for fiscal year 2021, that includes an amendment giving the US FDA the authority to recall drugs. Overall, the priorities and budget for the FDA in the minibus are unchanged from the bill approved by the House Appropriations Committee on July 9th, RAPS noted. The $3.2 billion funding recommendation is an increase of $40.8 million above its current funding levels. Total funding for the FDA, including revenue from user fees, is $5.99 billion. The House spending plan will now move to the U.S. Senate, but it is unknown when that legislating body will begin to examine the proposal. Learn More